Polyepitope hepatitis C antigen complex polypeptide vaccine and its prepn and application

A hepatitis C and polypeptide vaccine technology, applied in the field of molecular biology, can solve the problems such as the inability to find a breakthrough point in the development of hepatitis C vaccine
CN1223376CInactive Publication Date: 2005-10-19楚雄老拨云堂药业有限公司
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
楚雄老拨云堂药业有限公司
Publication Date
2005-10-19
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to molecular biological technology and aims at providing one kind of immunogenic hepatitis C vaccine to HCV virus with serious harm. The said polyepitope antigen complex polypeptide consists of 131 amino acids and has molecular weight of 13.8 KD and isopotential point of 8.3. Its preparation includes the steps of gene design, effective expression, separation and purification of expression product and preparation of polypeptide immunogen. Test data shows that the vaccine of the present invention has excellent scene of being used as hepatitis C preventing vaccine and detection and diagnosis material.
Need to check novelty before this filing date? Find Prior Art

Description

1. Technical field

[0001] The invention relates to the technical field of molecular biology, in particular to a vaccine prepared by using organisms. 2. Background technology

[0002] Viral hepatitis is a serious disease that endangers human health. Its pathogen is a class of hepatropic viruses with different structures. So far, there are 7 types of hepatitis viruses that have been discovered, and they are HAV, HBV, and HCV. , HDV, HEV and possibly TTV and HGV. The hepatitis caused by these hepatitis viruses all shows the necrosis of liver parenchymal cells, which has a serious pathological effect on the function of the liver, thus causing great harm to the human body. Since no effective antiviral drugs have been found so far, the prevention and treatment of various types of viral hepatitis focuses on the prevention of vaccines. With the advancement of biotechnology, the application of live attenuated hepatitis A vaccine and inactivated vaccine and hepatitis B genetically e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More